<DOC>
	<DOCNO>NCT00939913</DOCNO>
	<brief_summary>In patient undergo coronary angiography , incidence contrast induce nephropathy ( CIN ) vary widely range &lt; 5 % low risk patient , nearly 50 % high risk patient . Prior data show oral n-acetyl cysteine ( NAC ) effective reduce incidence CIN.Due extensive first pas metabolism , bioavailability oral NAC poor range 4 % -10 % . We hypothesize incidence CIN reduce patient ACS undergo PCI prophylactic administration intravenous NAC . This prospective , randomize , double-blind , placebo-controlled single center clinical trial design evaluate effect intravenous NAC patient acute coronary syndrome ( ACS ) undergo coronary angiography and/or percutaneous coronary intervention ( PCI ) . The medication Acetadote provide Cumberland Pharmaceuticals Inc ( www.cumberlandpharma.com ) . Patients exclude end-stage renal disease require dialysis , know hypersensitivity NAC history life-threatening contrast reaction . Primary end-point incidence CIN . Secondary end-points in-hospital mortality,30-day mortality , duration hospitalization change serum cystatin C level .</brief_summary>
	<brief_title>Effect Intravenous Acetadote Incidence Contrast Induced Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>1 . 18 year age old . 2 . Hospitalized primary diagnosis acute coronary syndrome . 3 . Scheduled coronary angiography intervention current hospitalization . 1 . Have endstage renal disease ( ESRD ) require dialysis . 2 . Have know hypersensitivity NAC . 3 . Have history lifethreatening contrast reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>contrast nephropathy</keyword>
	<keyword>intravenous n-acetlycysteine</keyword>
</DOC>